EMERGEX VACCINES
Emergex Vaccines offer affordable, practical and effective vaccines on-demand, which are suited to low resource environments, disproportionately affected by pandemics. These vaccines will be used to create a clinical grade international vaccine repository that will act as a first line of defence in the case of existing and newly emerging infectious disease outbreaks.
EMERGEX VACCINES
Industry:
Biopharma Biotechnology Health Care
Founded:
2016-01-01
Address:
Abingdon, Oxfordshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.emergexvaccines.com
Total Employee:
1+
Status:
Active
Total Funding:
12.99 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Google Tag Manager WordPress Google Universal Analytics Domain Not Resolving Apache
Current Employees Featured
Thomas Rademacher Founder and CEO @ Emergex Vaccines
Founder and CEO
2016-01-01
Storme Moore-Thornicroft Founder, Executive Director, Chief Operating Officer @ Emergex Vaccines
Founder, Executive Director, Chief Operating Officer
2016-01-01
Founder
Investors List
Department of Health and Social Care (DHSC)
Department of Health and Social Care (DHSC) investment in Grant - Emergex Vaccines
Vickers Venture Partners
Vickers Venture Partners investment in Series A - Emergex Vaccines
Innovate UK
Innovate UK investment in Grant - Emergex Vaccines
Trend Investment Group
Trend Investment Group investment in Seed Round - Emergex Vaccines
Official Site Inspections
http://www.emergexvaccines.com Semrush global rank: 3.51 M Semrush visits lastest month: 4.21 K
Unable to get host informations!!!
More informations about "Emergex Vaccines"
Home - Gylden Pharma
We work on addressing some of the world’s most impactful health threats with a growing pipeline of candidates. Gylden’s T cell-priming vaccine and immunotherapy candidates combine core proprietary technologies.First …See details»
Emergex Vaccines - Crunchbase Company Profile
Emergex Vaccines may be growing as evidenced by a series of recent developments. The company has secured a contract worth £1.79 million with …See details»
Emergex Vaccines Information - RocketReach
Emergex, a clinical-stage, privately-held biotechnology company headquartered in Abingdon, UK, with an operating subsidiary in Doylestown, Pennsylvania, USA, is pioneering the …See details»
EMERGEX VACCINES HOLDING LIMITED – Funding, Valuation, …
Oct 17, 2024 Emergex, a UK-based biotechnology company headquartered in Abingdon, UK, is pioneering the development of T-Cell Priming vaccines to address some of the world's most …See details»
Emergex Vaccines Company Profile | Management and Employees …
Www.emergexvaccines.com . Emergex Vaccines Profile and History. Emergex Vaccines Holding Limited is a biotechnology company focused on the development of vaccines against viral and …See details»
Emergex Vaccines - EU-Startups
Mar 4, 2022 Emergex focuses on developing vaccines that prevent virulent diseases such as Zika, Dengue Fever, Ebola and even pandemic Flu. The company’s set-point vaccines deliver …See details»
EMERGEX VACCINES LIMITED - Companies House
Jan 28, 2025 EMERGEX VACCINES LIMITED - Free company information from Companies House including registered office address, filing history, accounts, annual return, officers, …See details»
EMERGEX VACCINES LTD | Startup Profile and Investments
Emergex Vaccines is a pioneering UK biotechnology company that focuses on developing T cell-priming immune set-point candidates to combat infectious diseases. Founded in 2016, the …See details»
Company Spotlight: Emergex Vaccines | Milton Park
Jan 18, 2022 We recently caught up with Emergex Vaccines, eager to learn more about the company’s work developing a special kind of vaccine which could reduce regular booster jabs …See details»
Emergex Announces Company Name Change to “Gylden Pharma …
Oct 17, 2024 Abingdon, United Kingdom, 17 October 2024 – Emergex Vaccines Holding Limited, a clinical-stage biotechnology company that is addressing major global infectious …See details»
Emergex announces approval to initiate Phase I clinical
Nov 15, 2021 Email: smt@emergexvaccines.com Robin Cohen, Chief Commercial Officer Phone: +44 (0) 1235 527589 Email: rc@emergexvaccines.com: Chris Gardner / Ashley Tapp / …See details»
Emergex Vaccines Forms US Subsidiary (Emergex USA) by …
Sep 1, 2020 At the Company Emergex Storme Moore-Thornicroft, Executive Director Phone: +44 (0) 1235 527589 Email: smt@emergexvaccines.com Consilium Strategic Communications …See details»
Emergex Vaccines | VentureRadar
Emergex Vaccines is a clinical-stage, privately held biotechnology company headquartered near Oxford, UK, with R&D facilities in Milton Park, UK and... ... Find out ...See details»
Emergex announces approval to initiate Phase I clinical trial of its ...
Nov 15, 2021 Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats through the development of 100% synthetic T …See details»
Series A - Emergex Vaccines - 2020-01-09 - Crunchbase
Jan 9, 2020 Organization Name . Emergex Vaccines . Announced Date Jan 9, 2020; Funding Type Series A; Funding Stage Early Stage Venture; Money Raised . obfuscated. obfuscated. …See details»
Emergex Vaccines - VentureRadar
Emergex Vaccines is a clinical-stage, privately held biotechnology company headquartered near Oxford, UK, with R&D facilities in Milton Park, UK and... ... Find out ...See details»
Emergex Vaccines forms US subsidiary (Emergex USA) by …
Sep 1, 2020 Acquisition brings critical technical pre-clinical vaccine development capabilities in-house and establishes US based Emergex subsidiary Emergex uniquely develops novel 100% …See details»
Emergex T Cell-Priming Vaccine Candidate for Betacoronaviruses …
Oct 2, 2024 - NIAID will be conducting and sponsoring clinical trials to accelerate and to streamline the rapid development of next-generation COVID-19 vaccines. ABINGDON, United …See details»
Emergex Vaccines Forms US Subsidiary (Emergex USA) by
Sep 1, 2020 At the Company Emergex Storme Moore-Thornicroft, Executive Director Phone: +44 (0) 1235 527589 Email: smt@emergexvaccines.com Consilium Strategic Communications …See details»
Emergex confirms its next generation T-Cell Priming COVID-19 …
Dec 1, 2021 About Emergex . Emergex, a biotechnology company headquartered in Abingdon, UK, with an operating subsidiary in Doylestown, Pennsylvania, USA, is pioneering the …See details»